HSBC Holdings
ATRA icon

HSBC Holdings’s Atara Biotherapeutics ATRA Stock Holding History

HSBC Holdings’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-451
Closed -$7.82K – 2939
2024
Q1 		$7.82K Buy
+451
New +$8.01K ﹤0.01% 3019
2019
Q4 		– Sell
-485
Closed -$171K – 3027
2019
Q3 		$171K Buy
+485
New +$181K ﹤0.01% 2904
2018
Q3 		– Sell
-2,977
Closed -$2.73M – 2534
2018
Q2 		$2.73M Sell
2,977
-249
-8% -$267K ﹤0.01% 1398
2018
Q1 		$3.15M Buy
+3,226
New +$2.94M ﹤0.01% 1275

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

HSBC Holdings's ATRA Position: Q2 2024 in Review

HSBC Holdings sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 451 shares — an estimated $7.82K sold.

HSBC Holdings first reported a position in ATRA in Q1 2018 and held it in 4 quarters. The position peaked at $3.15M in Q1 2018. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • HSBC Holdings reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • HSBC Holdings sold 451 Atara Biotherapeutics shares in Q2 2024, an estimated $7.82K.
  • HSBC Holdings first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 4 quarters.
  • HSBC Holdings's Atara Biotherapeutics position peaked at $3.15M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on HSBC Holdings's 13F filing for Q2 2024, filed 12 Aug 2024.